Mechanism of action of bisphosphonates (original) (raw)

• Rodan GA, Reszka AA: Bisphosphonate mechanism of action. Curr Mol Med 2002, 2:571–577. jThis review discusses in greater detail the clinical aspects and tissuelevel actions of N-BPs.
  Article PubMed CAS Google Scholar
• Reszka AA, Rodan GA: Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003, 5:65–74.
  PubMed Google Scholar
• van Beek E, Hoekstra M, van de Ruit M, et al.: Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 1994, 9:1875–1882.
  PubMed CAS Google Scholar
• Sato M, Grasser W, Endo N, et al.: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88:2095–2105.
  PubMed CAS Google Scholar
• Azuma Y, Sato H, Oue Y, et al.: Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995, 16:235–245.
  Article PubMed CAS Google Scholar
• Masarachia P, Weinreb M, Balena R, et al.: Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996, 19:281–290.
  Article PubMed CAS Google Scholar
• Murakami H, Takahashi N, Sasaki T, et al.: A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995, 17:137–144.
  Article PubMed CAS Google Scholar
• Ito M, Amizuka N, Nakajima T, et al.: Bisphosphonate acts on osteoclasts independent of ruffled borders in osteosclerotic (oc/oc) mice. Bone 2001, 28:609–616.
  Article PubMed CAS Google Scholar
• Salo J, Lehenkari P, Mulari M, et al.: Removal of osteoclast bone resorption products by transcytosis. Science 1997, 276:270–273.
  Article PubMed CAS Google Scholar
• van Beek ER, Lowik CW, Papapoulos SE: Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 2002, 30:64–70.
  Article PubMed Google Scholar
• Frith JC, Rogers MJ: Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 2003, 18:204–212.
  Article PubMed CAS Google Scholar
• Halasy-Nagy JM, Rodan GA, Reszka AA: Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001, 29:553–559. This paper demonstrates the separation of bisphosphonates, based on suppression of bone resorption through induction of osteoclast apoptosis (eg, clodronate and etidronate) versus inhibition of osteoclast function (eg, N-BPs).
  Article PubMed CAS Google Scholar
• Klein G, Martin JB, Satre M: Methylenediphosphonate, a metabolic poison in dictyostelium discoideum. Phosphorus-31 NMR evidence for accumulation of adenosine 5′-(beta, gamma-methylenetriphosphate) and diadenosine 5′,5′′′-P1,P4-(P2,P3-methylenetetraphosphate). Biochemistry 1988, 27:1897–1901.
  Article CAS Google Scholar
• Auriola S, Frith J, Rogers MJ, et al.: Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 1997, 704:187–195.
  Article PubMed CAS Google Scholar
• Frith JC, Monkkonen J, Blackburn GM, et al.: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997, 12:1358–1367. This paper provides the first in vivo proof for the mechanism of action of clodronate in osteoclasts and macrophages.
  Article PubMed CAS Google Scholar
• Frith JC, Monkkonen J, Auriola S, et al.: The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001, 44:2201–2210.
  Article PubMed CAS Google Scholar
• Hughes DE, Wright KR, Uy HL, et al.: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995, 10:1478–1487.
  Article PubMed CAS Google Scholar
• Selander KS, Monkkonen J, Karhukorpi EK, et al.: Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996, 50:1127–1138.
  PubMed CAS Google Scholar
• Reszka AA, Halasy Nagy JM, Masarachia PJ, et al.: Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosispromoting kinase. J Biol Chem 1999, 274:34967–34973.
  Article PubMed CAS Google Scholar
• Lehenkari PP, Kellinsalmi M, Napankangas JP, et al.: Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002, 61:1255–1262.
  Article PubMed CAS Google Scholar
• Biller SA, Forster C, Gordon EM, et al.: Isoprenoid (phosphinylmethyl) phosphonates as inhibitors of squalene synthetase. J Med Chem 1988, 31:1869–1871.
  Article PubMed CAS Google Scholar
• Fisher JE, Rogers MJ, Halasy JM, et al.: Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999, 96:133–138. This paper provides the first demonstration that protein geranylgeranylation is the critical metabolic process inhibited by the N-BPs in the osteoclast. It demonstrates that restoration of geranylgeranylation, but not farnesylation or cholesterol synthesis, can restore osteoclast function in the presence of alendronate.
  Article PubMed CAS Google Scholar
• Luckman SP, Coxon FP, Ebetino FH, et al.: Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998, 13:1668–1678.
  Article PubMed CAS Google Scholar
• van Beek E, Lowik C, van der Pluijm G, et al.: The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999, 14:722–729. This paper demonstrates the importance of protein geranylgeranylation to osteoclast function and also demonstrates that restoring protein geranylgeranylation can block the N-BPs effects on bone resorption.
  Article Google Scholar
• Bergstrom JD, Bostedor RG, Masarachia PJ, et al.: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000, 373:231–241.
  Article PubMed CAS Google Scholar
• van Beek E, Pieterman E, Cohen L, et al.: Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999, 264:108–111.
  Article PubMed Google Scholar
• Dunford JE, Thompson K, Coxon FP, et al.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235–242.
  PubMed CAS Google Scholar
• Fisher JE, Rodan GA, Reszka AA: In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000, 141:4793–4796. This paper provides the first in vivo proof for N-BP suppression of the mevalonate pathway selectively in osteoclasts. It also shows that osteoclast numbers rise immediately following N-BP treatment, but not clodronate or etidronate.
  Article PubMed CAS Google Scholar
• Woo JT, Kasai S, Stern PH, et al.: Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J Bone Miner Res 2000, 15:650–662.
  Article PubMed CAS Google Scholar
• Dunford JE, Ebetino FH, Rogers MJ: The mechanism of inhibition of farnesyl diphosphate synthase by nitrogen-containing bisphosphonates. Bone 2002, 30:40S.
  Article Google Scholar
• Luckman SP, Hughes DE, Coxon FP, et al.: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581–589.
  Article PubMed CAS Google Scholar
• Coxon FP, Helfrich MH, Van’t Hof R, et al.: Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000, 15:1467–1476.
  Article PubMed CAS Google Scholar
• Alakangas A, Selander K, Mulari M, et al.: Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 2002, 70:40–47.
  Article PubMed CAS Google Scholar
• Glantschnig H, Rodan GA, Reszka AA: Alendronate mechanism of action: the role of geranylgeranylation in p70S6 kinase-dependent osteoclast survival. Bone 2002, 30:41S.
  Google Scholar
• Graves JD, Gotoh Y, Draves KE, et al.: Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J 1998, 17:2224–2234.
  Article PubMed CAS Google Scholar
• Glantschnig H, Rodan GA, Reszka AA: Mapping of MST1 kinase sites of phosphorylation. Activation and autophosphorylation. J Biol Chem 2002, 277:42987–42996.
  Article PubMed CAS Google Scholar
• Benford HL, Frith JC, Auriola S, et al.: Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999, 56:131–140.
  PubMed CAS Google Scholar
• Schenk R, Merz WA, Muhlbauer R, et al.: Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 1973, 11:196–214.
  Article PubMed CAS Google Scholar
• Selander K, Lehenkari P, Vaananen HK: The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int 1994, 55:368–375.
  Article PubMed CAS Google Scholar
• Kim TW, Yoshida Y, Yokoya K, et al.: An ultrastructural study of the effects of bisphosphonate administration on osteoclastic bone resorption during relapse of experimentally moved rat molars. Am J Orthod Dentofacial Orthop 1999, 115:645–653.
  Article PubMed CAS Google Scholar
• Zimolo Z, Wesolowski G, Rodan GA: Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest 1995, 96:2277–2283.
  Article PubMed CAS Google Scholar
• Zhao H, Ettala O, Vaananen HK: Intracellular membrane trafficking pathways in bone-resorbing osteoclasts revealed by cloning and subcellular localization studies of small GTPbinding rab proteins. Biochem Biophys Res Commun 2002, 293:1060–1065.
  Article PubMed CAS Google Scholar
• Zhao H, Laitala Leinonen T, Parikka V, et al.: Downregulation of small GTPase Rab7 impairs osteoclast polarization and bone resorption. J Biol Chem 2001, 276:39295–39302.
  Article PubMed CAS Google Scholar
• Zhang D, Udagawa N, Nakamura I, et al.: The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 1995, 108:2285–2292.
  PubMed CAS Google Scholar
• Razzouk S, Lieberherr M, Cournot G: Rac-GTPase, osteoclast cytoskeleton and bone resorption. Eur J Cell Biol 1999, 78:249–255.
  PubMed CAS Google Scholar
• Chellaiah MA, Soga N, Swanson S, et al.: RhoA is critical for osteoclast podosome organization, motility, and bone resorption. J Biol Chem 2000, 275:11993–12002.
  Article PubMed CAS Google Scholar
• Backlund PS Jr: Post-translational processing of RhoA. Carboxyl methylation of the carboxyl-terminal prenylcysteine increases the half-life of RhoA. J Biol Chem 1997, 272:33175–33180.
  Article PubMed CAS Google Scholar